Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| SARS-CoV-2-induced IgG repertoires shape T cell responses, microRNA r… IvIg · PMID 42604002 | Myopathies | Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source SARS-CoV-2 infection can generate IgG repertoires with functions beyond viral neutralization. We purified IgG from non-… | Journal of translational autoimmunity 2026-08-16 13:24:24 | Source |
| The economic value of self-administered subcutaneous immunoglobulin G… IvIg · PMID 41701183 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Subcutaneous immunoglobulin (SCIg) is a treatment available in Canada for patients requiring antibody replacement. Whil… | Journal of medical economics 2026-08-16 13:24:24 | Source |
| Antigen-specific IgY as an orally deliverable biomaterial for sustain… Behavioral Interventions for Controlling Oral Behaviors · PMID 42140132 | Myopathies | Immunomodulation | Publication | PubMed | Voir la publication source Over the past decades, antibodies have become indispensable tools due to their high specificity and versatility. Egg yo… | Colloids and surfaces. B, Biointerfaces 2026-08-16 13:24:23 | Source |
| Awareness of the link between HPV and cancer according to cancer type… Behavioral Interventions for Controlling Oral Behaviors · PMID 41549778 | Cancer | À vérifier | Publication | PubMed | Voir la publication source While sociodemographic differences in the population awareness of the link between HPV and HPV-associated cancers have… | Human vaccines & immunotherapeutics 2026-08-16 13:24:23 | Source |
| Treadmill exercise partially attenuates bisphenol A-associated behavi… Behavioral Interventions for Controlling Oral Behaviors · PMID 42480732 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Environmental chemical exposure may influence behavior through coordinated physiological changes, but whether lifestyle… | Physiology & behavior 2026-08-16 13:24:23 | Source |
| Comparative efficacy of intralesional therapies for keloid scars: a n… Botulinum Toxin Type A for Injection · PMID 41860092 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Keloids are pathological scars causing pain, pruritus, and emotional distress. While common treatments exist, emerging… | Annals of medicine 2026-08-16 13:24:22 | Source |
| Efficacy and durability of therapies for neurogenic lower urinary tra… Botulinum Toxin Type A for Injection · PMID 42203154 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source To evaluate the short-term efficacy and long-term sustainability of botulinum toxin A (BTA), instillations, and neuromo… | Toxicon : official journal of the International Societ… 2026-08-16 13:24:22 | Source |
| Anatomical Variation of Absent Facial Vein: Implications for Facial R… Functional muscle transfer · PMID 41948882 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source The facial vein is the standard recipient vessel in facial reanimation surgery. Its complete absence is rarely describe… | Head & neck 2026-08-16 13:24:19 | Source |
| Immediate and single-stage facial reanimation after radical parotidec… Functional muscle transfer · PMID 42495572 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Radical parotidectomy with facial nerve sacrifice produces major functional and aesthetic deficits. Immediate or single… | JPRAS open 2026-08-16 13:24:19 | Source |
| Identification of novel small molecule compounds with readthrough act… Ataluren · PMID 42034525 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Nagashima-type palmoplantar keratosis (NPPK), the most common form of hereditary palmoplantar keratodermas in East Asia… | Journal of dermatological science 2026-08-16 13:24:13 | Source |
| Community-acquired pneumonia outside the intensive care unit: Clinica… Chronic Corticosteroid Therapy · PMID 42468735 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source To describe the clinical, radiological, and microbiological characteristics of community-acquired pneumonia (CAP) manag… | International journal of infectious diseases : IJID :… 2026-08-16 13:24:12 | Source |
| The Impact of "Fear of Falling" on Physical Performance, Balance, and… Fear of Falling in Muscular Dystrophy · PMID 36030791 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source The aim of this study was to investigate falls and the fear of falling (FOF) in children with Duchenne muscular dystrop… | Neuropediatrics 2026-08-16 13:24:10 | Source |
| Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitor… Tadalafil · PMID 41876378 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source To compare the real-world safety profiles of α1-adrenoceptor antagonists (α1-blockers), 5α-reductase inhibitors (5ARIs)… | The aging male : the official journal of the Internati… 2026-08-16 13:24:09 | Source |
| Real-world outcomes of tadalafil plus mirabegron combination therapy… Tadalafil · PMID 41879268 | Myopathies | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Men with mixed lower urinary tract symptoms (LUTS) often have storage symptoms that drive bother and quality-of-life im… | The aging male : the official journal of the Internati… 2026-08-16 13:24:09 | Source |
| Bone defect repair materials after bone tumour resection: from struct… Limb salvage · PMID 42500946 | Myopathies | Remyélinisation indirecte / réparation · Immunomodulation | Publication | PubMed | Voir la publication source Critical-sized bone defects following malignant tumour resection remain among the most difficult challenges in orthopae… | Annals of medicine 2026-08-16 13:24:08 | Source |
| Successful limb salvage using a fresh maternal great saphenous vein a… Limb salvage · PMID 42502441 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Major vascular trauma in children is rare and presents significant reconstructive challenges when autologous conduit op… | Journal of vascular surgery cases and innovative techn… 2026-08-16 13:24:08 | Source |
| The extravascular plaque modulation technique: A novel strategy to fa… Limb salvage · PMID 42502446 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Severely calcified infrapopliteal chronic total occlusions (CTOs) remain a major limitation in endovascular limb salvag… | Journal of vascular surgery cases and innovative techn… 2026-08-16 13:24:08 | Source |
| Breakthroughs and insights: A comprehensive review of yellow fever va… Yellow Fever vaccine (17D) · PMID 39577331 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source The yellow fever vaccine 17D is one of the most successful live-attenuated vaccines ever developed, controlling mosquit… | Vaccine 2026-08-16 13:24:07 | Source |
| Blunt Tibial Injury Is Associated With Primary Amputation for Lower E… Primary major amputation · PMID 42107181 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Single-center civilian series report up to a 20% primary amputation rate following lower-extremity vascular trauma (LEV… | The Journal of surgical research 2026-08-16 13:24:05 | Source |
| Contemporary Outcomes of Staged Versus Primary Major Amputation for S… Primary major amputation · PMID 42349641 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Lower extremity amputation is a necessary, life-saving intervention for patients with severe foot infection. Previous s… | Annals of vascular surgery 2026-08-16 13:24:04 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||